Stifel analyst Thomas Stephan lowered the firm’s price target on Staar Surgical to $40 from $45 and keeps a Hold rating on the shares following last week’s investor day meeting. The firm highlights what it sees as a “low bar” for long-term market-level U.S. share gains and a “higher bar” for U.S. share gains on a practice-by-practice basis. The firm also calls operating margin goals “achievable at the low-end/midpoint but more challenging at the high-end.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on STAA:
- Shake Shack upgraded, DoorDash downgraded: Wall Street’s top analyst calls
- Staar Surgical price target lowered to $52 from $54 at Needham
- Staar Surgical price target lowered to $45 from $50 at Piper Sandler
- Staar Surgical downgraded to Hold from Buy at Benchmark
- Staar Surgical sees FY26 sales $500M-$550M, operating margin of 12%-16%